105 / 154
A B S T R A C T S
S75
P066
THE USE OF DOSE-DENSE WEEKLY PACLITAXEL (WP)
CHEMOTHERAPY IN GERIATRIC PATIENTS WITH
GYNAECOLOGICAL CANCERS
A. Pericao
1,
*, F. El-Khouly
1
, M. McCormack
1
, R. Kristeleit
1
,
J. Ledermann
1
, R. Miller
1
1
University College London Hospital, London, United Kingdom
Introduction:
Gynaecological cancers are the 4th leading
cause of cancer deaths in females, with over 5000 cases
diagnosed in those
65 years annually in the UK. WP
chemotherapy is often used for the treatment of advanced
disease aiming to improve quality of life and control
symptoms. The expectation is that shortage of interval of
doses will be more effective on killing tumor-cells and prolong
survival. However, concerns over toxicity and comorbidities
may restrict use in the elderly.
Objectives:
We sought to examine the tolerance and
outcome of elderly patients (pts) treated with dose-dense WP
for gynaecological malignancies over a five-year period at a
single institution.
Methods:
Clinical records of pts
65, treated withWP over a
5-year period were reviewed. Details regarding chemotherapy
toxicity, duration of treatment, response to chemotherapy
and co-morbidities were recorded.
Results:
79 women
65 years (median 72, range 65-
86) treated with WP (80 mg/m 2 days 1,8,15 q21 days) were
identified. 73, (89%) and 6 (11%) received WP for ovarian and
endometrial cancer respectively. Median number of cycles
received was 4 (range 1-6) with 72% of patients receiving full
dose with every cycle. 23 pts (29%) required a dose reduction
(DR), 7 pts (9%) were DR from cycle 1 due to concerns over
age or poor ECOG performance status. The remainder
underwent subsequent DRs, commonly for neuropathy
(14%) and fatigue (3%). WP was discontinued due to toxicity
in 3 (3.8%) and medical co-morbidities in 1. 46% of pts had
at
1 significant co-morbidity, most commonly hypertension
30 (37.9%) and hypercholestorolaemia 11 (22.78%). Partial or
complete response, stable disease and progressive disease
were observed in 38.0%, 20.0% and 42.2% of evaluable (n=71)
pts respectively.
Conclusion:
WP was well tolerated in pts
65 years.
Response rates are comparable to that seen in the general
gynaecological population.
References
:
[1] Kumar S, Mahdi H, Bryant C, Shah JP, Garg G, Munkarah A.
Clinical trials andprogresswithpaclitaxel inovarian cancer.
International Journal of Women’s Health. 2010;2:411-427.
doi:10.2147/IJWH.S7012.
[2] John K. Chan, M.D., Mark F. Brady, Ph.D., Richard T. Penson,
M.D., Helen Huang, M.S., Michael J. Birrer, M.D., Ph.D.,
Joan L. Walker, M.D., Paul A. DiSilvestro, M.D., Stephen C.
Rubin, M.D., Lainie P. Martin, M.D., Susan A. Davidson, M.D.,
Warner K. Huh, M.D., David M. O’Malley, M.D., Matthew P.
Boente, M.D., Helen Michael, M.D., and Bradley J. Monk,
M.D. Weekly vs. Every-3-Week Paclitaxel and Carboplatin
for Ovarian Cancer. The New England Journal of Medicine.
2016; 374:738-748. DOI: 10.1056/NEJMoa1505067.
[3] Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.
Optimal chemotherapy treatment for women with recurrent
ovarian cancer. Current Oncology. 2007;14(5):195-208.
[4] Högberg T1, Glimelius B, Nygren P; SBU-group. Swedish
Council of Technology Assessment in Health Care. A
systematic overview of chemotherapy effects in ovarian
cancer. Acta Oncol. 2001;40(2-3):340-60.
[5] Wiseman LR1, Spencer CM. Paclitaxel. An update of its use
in the treatment of metastatic breast cancer and ovarian
and other gynaecological cancers. Drugs Aging. 1998
Apr;12(4):305-34.
Disclosure of interest:
None declared
Keywords:
Dose-dense weekly, endometrial cancer, ovarian
cancer, paclitaxel
P067
THE EFFECT OF AGE ON PATIENT REPORTED OUTCOMES
FOLLOWING RADICAL PROSTATE RADIOTHERAPY
A. Nuhoglu Savas
1,
*, L. Sellers
2
, A. Al-Abdullah
2
,
R. Ramiswami
3
, R. Davda
2
, A. V. Mitra
2
, H. Payne
2
1
Department of Medical Physics and Biomedical Engineering,
University College London,
2
Department of Oncology, University
College London Hospital,
3
Department of Oncology, Charing Cross
Hospital, London, United Kingdom
Introduction:
Patient reported outcomes of older men
receiving radical radiotherapy to the prostate is increasingly
important as the age of the general population rises and more
older men are diagnosed with and treated for prostate cancer.A
significant number of older men with high-risk prostate cancer
do not receive radical treatment. Potential explanations for the
apparent under treatment of older men may be beliefs that
older men are at increased risk of death from co-morbidities
and concerns regarding treatment related toxicity.
Reports on the impact of age on toxicity following radical
prostate radiotherapy are conflicting. Collection of patient
reported outcome measures (PROMs) including the Expanded
Prostate Cancer Index Composite for Clinical Practice (EPIC-CP)
Table 1 (abstract P067)
Total EPIC
Urinary Domain
Bowel Symptom Score
Hormonal/Vitality Score
All
17.2(±17.738)
4.46(±8.369)
2.15(±6.232)
4.2(±7.173)
<70
16.95 (±17.502)
p=0.67
4.34 (8.153)
p=0.12
2.08(±6.154)
p=0.88
4.12(±7.056)
p=0.31
70-74
17.49(±17.385)
4.38 (±8.134)
2.15 (±6.311)
4.36(±7.134)
75
17.28 (±17.698)
4.39(±8.310)
2.11(±6.193)
4.44 (±7.173)
No statistically significant difference was detected in total EPIC-CP total score or urinary, bowel or hormonal scores between the different age
ranges.